Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ALKS with free AI briefings, catalyst countdowns, and dilution alerts.

ALKS · Alkermes plc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$787.4M Cash on Hand
CF+ Cash Runway
Follow ALKS by email Get an email when ALKS reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ALKS, unsubscribe in one click. Privacy

📣 What ALKS Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Aripiprazole Lauroxil
FDA approved Oct 2015 · Aristada
Schizophrenia Phase 4 · NCT04203056 Terminated
Naltrexone
FDA approved Apr 2006 · Vivitrol
Opioid-Related Disorders Phase 4 · NCT02978417 Completed
Olanzapine And Samidorphan L-Malate
FDA approved May 2021 · Lybalvi
Focus of Study is on Healthy Lactating Women Phase 1 · NCT05547100 Completed
XR-NTX Alcohol Use Disorder Phase 4 · NCT05028062 Recruiting
Norepinephrine Reuptake Inhibitor Schizophrenia Phase 4 · NCT04203056 Terminated
ALKS 2680 Narcolepsy Type 1 Phase 2/3 · NCT06767683 Recruiting
S-Adenosylmethionine Schizophrenia Phase 3 · NCT05303064 Recruiting
ALKS 5461 Major Depressive Disorder Phase 3 · NCT02158533 Completed
injected insulin Diabetes Mellitus Phase 3 · NCT00157339 Completed
Injectable insulin Diabetes Mellitus, Type 2 Phase 3 · NCT00325364 Completed
Human Insulin Inhalation Powder Diabetes Mellitus Phase 3 · NCT00157339 Completed
Naloxone Heroin Dependence Phase 3 · NCT03711318 Terminated
Alixorexton Narcolepsy Type 2 Phase 3 · NCT07502443 Recruiting
ALKS 8700 Multiple Sclerosis Phase 3 · NCT02634307 Completed
ALKS 3831 Schizophrenia Phase 3 · NCT03201757 Completed
Active Cannabis Cannabis Phase 2 · NCT04576507 Completed

Also used in these trials (approved or third-party drugs, not ALKS's own candidates): Paliperidone Palmitate, Olanzapine, Insulin Glargine, Dimethyl Fumarate.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ALKS holds $787.4M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ALKS files for a raise →

👥 Who Owns ALKS

Insiders 0.6% Institutions (562 holders) 99.4% Public and other holders 0%
HolderTypeShares% of sharesAs of
Baker Bros. Advisors LP Institution (13G, 5%+) 10,012,267 5.96% 2025-12-31
Vanguard Portfolio Management Institution (13G, 5%+) 9,647,056 5.74% 2026-03-31
Vanguard Capital Management Institution (13G, 5%+) 8,676,888 5.16% 2026-03-31
Blair Curtis Jackson
President & CEO, Alkermes plc, Director · +263,283 options
Insider 241,308 0.14% 2026-02-26
David Joseph Gaffin
EVP, CLO, Alkermes, Inc. · +114,656 options
Insider 219,353 0.13% 2026-11-03
Shane Cooke
Director · +16,947 options
Insider 106,679 0.06% 2026-05-20
Christian Todd Nichols
SVP, Chief Commercial Officer · +97,284 options
Insider 102,193 0.06% 2026-08-17
Craig C. Hopkinson
EVP R&D, Chief Medical Officer · +184,133 options
Insider 65,389 0.04% 2026-09-01
Brian P Mckeon
Director · +11,538 options
Insider 48,536 0.03% 2026-05-20
nancy lynn MD snyderman
Director · +11,538 options
Insider 36,178 0.02% 2026-08-03
Richard Gaynor
Director · +11,538 options
Insider 35,751 0.02% 2026-05-20
Frank Anders Wilson
Director · +11,538 options
Insider 35,751 0.02% 2026-05-20

Share count 168,043,540 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full ALKS picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ALKS and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.